We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 5.00 | 0.29% | 1,733.50 | 1,732.50 | 1,733.00 | 1,739.50 | 1,724.50 | 1,733.00 | 4,237,056 | 16:35:18 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.48 | 71.35B |
From May 2021 to May 2024
By Colin Kellaher
ViiV Healthcare, the specialist HIV company majority owned by GlaxoSmithKline PLC, on Tuesday said the U.S. Food and Drug Administration granted priority review to its cabotegravir long-acting pre-exposure prophylaxis, or PrEP, therapy.
ViiV said cabotegravir, if approved, would be the first, long-acting therapy for the prevention of HIV for individuals at risk of sexually acquired HIV-1 infection who have a negative HIV-1 test prior to initiation.
The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period. ViiV said the agency set a target action date of Jan. 24, 2022, for the application.
ViiV, formed in November 2009, is majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi & Co. as shareholders. The company said it plans to initiate submissions of cabotegravir long-acting for PrEP to other regulatory authorities by the end of the year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 28, 2021 07:57 ET (11:57 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
